Application of 2-amino-6-vinylpurine as an efficient agent for conjugation of oligonucleotides

Nucleosides, Nucleotides and Nucleic Acids

Volumn 25, Issue 2, 2006, Pages 159-169

  Ali, Md Monsur ^a,b   Nagatsugi, Fumi ^a,b   Sasaki, Shigeki ^a,b,c   Nakahara, Ryusuke ^a   Maeda, Minoru ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c NONE   (Japan)

Author keywords

2 Amino 6 vinylpurine; Antisense; Conjugation; Oligodeoxynucleotide

Indexed keywords

2 AMINO 6 VINYLPURINE NUCLEOSIDE; ALKALI; GLUTATHIONE; OLIGONUCLEOTIDE; PURINE NUCLEOSIDE DERIVATIVE; UNCLASSIFIED DRUG;

ACIDITY; ARTICLE; CHEMICAL REACTION; CONJUGATE; MOLECULAR STABILITY;

OLIGONUCLEOTIDES; POLYMERS; PURINES; VINYL COMPOUNDS;

EID: 31644436268     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770500446873     Document Type: Article

References (56)

1. Tavitian, B. In vivo antisense imaging. Q. J. Nucl. Med. 2000, 44, 236-255.
2. Shi, N.; Boado, R.J.; Pardridge, W.M. Antisense imaging of gene expression in the brain in vivo. Proc. Natl. Acad. Sci. USA 2000, 97, 14709-14714.
3. Lee, H. J.; Boado, R. J.; Braasch, D. A.; Corey, R. D.; Pardridge, R. J. Imaging gene expression in the brain in vivo in a transgenic mouse model of Huntington's disease with an antisense radiopharmaceutical and drug-targeting technology. J. Nucl. Med. 2002, 43, 948-956.
4. Sato, N.; Kobayashi, H.; Saga, T.; Nakamoto, Y.; Ishimori, T.; Togashi, K.; Fujibayashi, Y.; Konishi, J.; Brechbiel, M.W. Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice. Clin. Canc. Res. 2001, 7, 3606-3612.
5. Urbain, J.-L. Oncogenes, cancer and imaging. J. Nucl. Med. 1999, 40, 498-501.
6. Crika, J.L. Stains, labels and detection strategies for nucleic acids assays. Ann. Clin. Biochem. 2002, 39, 114-129.
7. Zhang, M.; Creese, I. Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: Behavioral correlates. Neurosci. Lett. 1993, 161, 223-226.
8. Weiss, B.; Zhou, L.W.; Zhang, S.P.; Qin, Z.H. Antisense oligodeoxynucleotide inhibits D2 dopamine receptor-mediated behavior and D2 messenger RNA. Neuroscience 1993, 55, 607-612.
9. Papucci, L.; Schiavone, N.; Donnini, M.; Lapucci, A.; Luzi, E.; Tempestini, A.; Witort, E.; Capaccioli, S. Phosphodiester oligonucleotides inhibit mitosis and trigger apoptosis by a non-antisense, p53-mediated mechanism. Antisense Nucleic Acid Drug Dev. 2002, 12, 21-31.
10. Uhlmann, E.; Peyman, A. Antisense oligonucleotides-a new therapeutic principle. Chem. Rev. 1990, 90, 543-484.
11. Agrawal, S.; Zhao, Q. Antisense therapeutics. Curr. Opin. Chem. Biol. 1998, 2, 519-528.
12. Stein, C.A. Keeping the biotechnology of antisense in context. Nature Biotechnol. 1999, 17, 209.
13. Hnatowich, D.J. Antisense and nuclear medicine. J. Nucl. Med. 1999, 40, 693-707.
14. Astriab-Fisher, A.; Sergueev, D.S.; Fisher, M.; Shaw, B.R.; Juliano, L.L. Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates. Biochem. Pharmacol. 2000, 60, 83-90.
15. Milne, L.; Xu, Y.; Perrin, D.M.; Sigman, D.F. An approach to gene-specific transcription inhibition using oligonucleotides complementary to the template strand of the open complex. Proc. Natl. Acad. Sci. USA 2000, 97, 3136-3141.
16. Lau, Q.C.; Achenbach, T.V.; Borchers, O.; Muller, R.; Slater, E.P. In vivo pro-apoptotic and antitumor efficacy of a c-raf antisense phosphorothioate oligonucleotide: Relationship to tumor size. Antisense Nucleic Acid Drug Dev. 2002, 12, 11-20.
17. Manoharan, M. Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action. Antisense Nucleic Acid Drug Dev. 2002, 12, 103-128.
18. Dolle, F.; Hinnen, F.; Voufrey, F.; Tavitian, B.; Couzel, C. A general method for labeling oligodeoxynucleotides with F-18 for in vivo PET imaging. J. Label. Comp. Pharm. 1997, 39, 319-330.
19. Zhang, Y.-M.; Wang, Y.; Liu, N.; Zhu, Z.-H.; Rusckowski, M.; Hnatowich, D.J. In vitro investigations of tumor targeting with 99(m)Tc-labeled antisense DNA. J. Nucl. Med. 2001, 42, 1660-1669.
20. Fujibayashi, Y.; Yoshimi, E.; Waki, A.; Sakahara, H.; Saga, T.; Konishi, J.; Yonekura, Y.; Yokoyama, A. A novel In-111-labeled antisense DNA probe with multi-chelating sites (MCS probe) showing high specific radioactivity and labeling efficiency. Nucl. Med. Biol. 1999, 26, 17-21.
21. Tsuji, A.; Koshimoto, H.; Sato, Y.; Hirano, M.; Sei-Iida, Y.; Kondo, S.; Ishibashi, K. Direct observation of specific messenger RNA in a single living cell under a fluorescence microscope. Biophys. J. 2000, 78, 3260-3274.
22. Kurata, S.; Kanagawa, T.; Yamada, K.; Torimura, M.; Yokomaku, T.; Kamagata, Y.; Kurane, R. Fluorescent quenching-based quantitative detection of specific DNA/RNA using a BODIPY® FL-labeled probe or primer. Nucleic Acids Res. 2001, 29, e34.
23. Yamana, K.; Iwase, R.; Furutani, S.; Tsuchida, H.; Zako, H.; Yamaoka, T.; Murakami, A. 2′-Pyrene modified oligonucleotide provides a highly sensitive fluorescent probe of RNA. Nucleic Acids Res. 1999, 27, 2387-2392.
24. Hogrefe, R.I. An antisense oligonucleotide primer. Antisense Nucleic Acid Drug Dev. 1999, 9, 351-357.
25. Lazowski, K.W.; Kaczmarek L. Highly sensitive detection of hybridization of oligonucleotides to specific sequences of nucleic acids by application of fluorescence resonance energy transfer. Antisense Nucleic Acid Drug Dev. 2000, 10, 97-103.
26. Budil, D.E.; Kolaczkowski, S.V.; Perry, A.; Varaprasad, C.; Johnson, C.; Straus, P.R. Dynamics and ordering in a spin-labeled oligonucleotide observed by 220 GHz electron paramagnetic resonance. Biophys. J. 2000, 78, 430-438.
27. Thomas, F.; Michon, J.; Lhomme, J. Interaction of a spin-labeled adenine-acridine conjugate with a DNA duplex containing an abasic site model. Biochemistry 1999, 38, 1930-1937.
28. Gopalan, V.; Kuhne, H.; Biswas, R.; Li, H.; Brudvig, G.W.; Altman, S. Mapping RNA-protein interactions in ribonuclease P from Escherichia coli using electron paramagnetic resonance spectroscopy. Biochemistry 1999, 38, 1705-1714.
29. Ma, W.P.; Hamilton, S.E.; Stowell, J.G.; Byrn, S.R.; Davisson, V.J. Sequence specific cleavage of messenger RNA by a modified ribonucleaseH. Bioorg. Med. Chem. 1994, 2, 169-179.
30. Walton, C.M.; Wu, C.H.; Wu, G.Y. A ribonuclease H-oligo DNA conjugate that specifically cleaves hepatitis B viral messenger RNA. Bioconjugate Chem. 2001, 12, 770-775.
31. Fukuma, T.; Walton, C.M.; Wu, C.H.; Wu, G.Y. Conjugation of an antisense oligodeoxynucleotide to ribonuclease H results in sequence-specific cleavage and intracellular inhibition of HCV gene expression. Bioconjugate Chem. 2003, 14, 295-301.
32. Jeong, J.H.; Kim, S.W.; Park, G.T. A new antisense oligonucleotide delivery system based on self-assembled ODN-PEG hybrid conjugate micelles. J. Contr. Release 2003, 93, 183-191.
33. Oishi, M.; Sasaki, S.; Nagasaki, Y.; Kataoka, K. PH-Responsive oligodeoxynucleotide (ODN)-poly(ethylene glycol) conjugate through acid-labile beta-thiopropionate linkage: Preparation and polyion complex micelle formation. Biomacromolecules 2003, 4, 1426-1432.
34. Chirila, T.V.; Rakoczy, P.E.; Garrett, K.L.; Lou, X.; Constable, I.J. A recent review: The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides. Biomaterials 2002, 23, 321-342.
35. Kyriakides, T.R.; Cheung, C.Y.; Murthy, N.; Bornstein, P.; Stayton, P.S.; Hoffman, A.S. pH-Sensitive polymers that enhance intracellular drug delivery in vivo. J. Cont. Release 2002, 78, 295-303.
36. Rudolph, C.; Plank, C.; Lausier, J.; Schillinger, U.; Muller, R.H. Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells. J. Biol. Chem. 2003, 278, 11411-11418.
37. Moulton, H.M.; Hase, M.C.; Smith, K.M.; Iversen, P.L. HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev. 2003, 13, 31-43.
38. Viladkar, S. M. Guanine rich oligonucleotide-amino acid/Peptide conjugates: Preparation and characterization. Tetrahedron 2002, 58, 495-502.
39. Vives, E.; Lebleu, B. Selective coupling of a highly basic peptide to an oligonucleotide. Tetrahedron Lett. 1997, 38, 1183-1186.
40. Chen, C.P.; Zhang, L.R.; Peng, Y.F.; Wang, X.B.; Zhang, L.H. A concise method for the preparation of peptide and arginine-rich peptide-conjugated antisense oligonucleotide. Bioconjugate Chem. 2003, 14, 532-538.
41. Zubin, E.M.; Romanova, E.A.; Volkov, E.M.; Tashlitsky, V.N.; Korshunova, E.A.; Shabarova, Z.A.; Oretskaya, T.S. Oligonucleotide-peptide conjugates as potential antisense agents. FEBS Lett. 1999, 456, 59-62.
42. Anno, Y.; Kubo, T.; Ueki, R.; Yano, M.; Sasaki, K.; Ohba, H.; Fujii, M. Synthesis of DNA conjugates by solid-phase fragment condensation. Nucleos. Nucleot. Nucleic Acids 2003, 22, 1451-1453.
43. Hovinen, J.; Guzaev, A.; Azhayeva, E.; Azhayev, A.; Lonnberg, H. Imidazole tethered oligodeoxyribonucleotides-synthesis and RNA cleaving activity. J. Org. Chem. 1995, 60, 2205-2209.
44. MacMillan, A.M.; Verdine, G.L. Engineering tethered DNA-molecules by the convertible nucleoside approach. Tetrahedron 1991, 47, 2603-2616.
45. Nagatsugi, F.; Uemura, K.; Nakashima, S.; Maeda, M.; Sasaki, S. 6-Vinylated guanosine as a novel cross-linking agent and its versatile synthesis from the 6-O-tosylate by Pd(0)-catalyzed cross-coupling. Tetrahedron Lett. 1995, 36, 421-124.
46. Nagatsugi, F.; Uemura, K.; Nakashima, S.; Maeda, M.; Sasaki, S. 2-Aminopurine derivatives with C6-substituted olefin as novel cross-linking agents and the synthesis of the corresponding beta-phosphoramidite precursors. Tetrahedron 1997, 53, 3035-3044.
47. Nagatsugi, F.; Kawasaki, T.; Usui, D.; Maeda, M.; Sasaki, S. Highly efficient and selective cross-linking to cytidine based on a new strategy for auto-activation within a duplex. J. Am. Chem. Soc. 1999, 121, 6753-6754.
48. Kawasaki, T.; Nagatsugi, F.; Ali, M.M.; Maeda, M.; Sugiyama, K.; Hori, K.; Sasaki, S. Hybridization-promoted and cytidine-selective activation for cross-linking with the use of 2-amino-6-vinylpurine derivatives. J. Org. Chem. 2005, 70, 14-23.
49. Nagatsugi, F.; Kawasaki, T.; Tokuda, N.: Maeda, M.; Sasaki, S. Site-directed alkylation to cytidine within duplex by the oligonucleotides containing functional nucleobases. Nucleos. Nucleot. Nucleic Acids 2001, 20(4-7), 915-919.
50. Nagatsugi, F.; Usui, D.; Kawasaki, T.; Maeda, M.; Sasaki, S. Selective reaction to a flipping cytidine of the duplex DNA mediated by triple helix formation. Bioorg. Med. Chem. Lett. 2001, 11, 343-345.
51. Nagatsugi, F.; Matsuyama, Y.; Maeda, M.; Sasaki, S. Selective cross-linking to the adenine of the TA interrupting site within the triple helix. Bioorg. Med. Chem. Lett. 2002, 12, 487-489.
52. Nagatsugi, F.; Sasaki, S.; Miller, P.S.; Seidman M.M. Site-specific mutagenesis by triple helix-forming oligonucleotides containing a reactive nucleoside analog. Nucleic. Acids Res. 2003, 31, e31.
53. Mishra, M.; Bennett, J. R.; Chaudhuri, G. Increased efficacy of antileishmanial antisense phosphorothioate oligonucleotides in Leishmania amazonensis overexpressing ribonuclease H. Biochemical Pharmacol. 2001, 61, 467-476.
54. Futaki, S.; Suzuki, T.; Ohashi, W.; Yagami, T.; Tanaka, S.; Ueda, K.; Sugiura, Y. Arginine-rich peptides - An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 2001, 276, 5836-5840.
55. Futaki, S.; Nakase, I.; Suzuki, T.; Youjun, Z.; Sugiura, Y. Translocation of branched-chain arginine peptides through cell membranes: Flexibility in the spatial disposition of positive charges in membrane-permeable peptides. Biochemistry 2002, 41, 7925-7930.
56. Futaki, S. Arginine-rich peptides: Potential for intracellular delivery of macromolecules and the mystery of the translocation mechanisms. Int. J. Pharm. 2002, 245, 1-7.